Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)
May 3, 2024 11:33 AM EDTUpdated 01:56 PM
Deals
Manufacturing

FTC wants more in­for­ma­tion on No­vo-Catal­ent deal in an­titrust re­view

Anna Brown

News Reporter

The Fed­er­al Trade Com­mis­sion has ex­tend­ed its an­titrust re­view of No­vo Hold­ings’ $16.5 bil­lion pur­chase of Catal­ent by po­ten­tial­ly an­oth­er 30 days as it re­quests …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times